Cormorant Asset Management »

Mersana Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Mersana Therapeutics (MRSN) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Mersana Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mersana Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mersana Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $12M 2.6M 4.48
2017-12-31 $4.9M 296k 16.43
2017-09-30 $5.1M 296k 17.29
2017-06-30 $1.1M 80k 13.97

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Mersana Therapeutics

EcoR1 Capital
VR Adviser
Bain Capital Life Sciences Investors
BlackRock
Vanguard Group
Nextech Invest
Balyasny Asset Management
Citadel Advisors
Rock Springs Capital Management
Morgan Stanley
Woodline Partners
Cormorant Asset Management
Geode Capital Management
Deutsche Bank Aktiengesellschaft
Millennium Management

View all funds holding Mersana Therapeutics